Bioequivalence Study Of Pediatric Appropriate Formulation

Completed · Phase 1

Conditions studied: Hypercholesterolemia

In brief

To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.

Key facts

Study ID

NCT00758004

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

76

Starts

2008-10-01

Expected to finish

2009-03-01

Last updated by the study team

2021-02-18

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female volunteers
• Mass Index (BMI) of approximately 18 to 30 kg/m2

You may not qualify if…

• Any condition possibly affecting drug absorption
• A positive urine drug screening

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.